Close Menu

Caribou Biosciences

The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.

As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.

CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.

The two studies describe methods for identifying off-target mutations associated with cell-type-specific SNPs and detecting potential off-target cleavage sites.

The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.

After CRISPR/Cas9 makes a double-strand break in DNA and the cell repairs it, the same set of mutations crop up again and again based on the genomic sequence.

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

Caribou will license its CRISPR technology to Genus to help it create pigs that are resistant to Porcine Reproductive and Respiratory Syndrome Virus.

The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.

The Berkeley, California-based company is aiming to turn CRISPR into a platform technology for clinical and industrial applications.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.